Investigating ways to prevent malaria during pregnancy to improve birth outcomes in Africa
Examining the mechanisms and optimization of malaria chemoprevention strategies to improve birth outcomes in Africa
This study is looking at how two different malaria treatments for pregnant women can help improve the health of both moms and their babies in Africa, focusing on reducing low birth weight and other health issues.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10890683 on NIH RePORTER |
What this research studies
This research focuses on improving birth outcomes in Africa by examining malaria prevention strategies for pregnant women. It evaluates the effectiveness of a specific treatment called dihydroartemisinin-piperaquine (DP) compared to the standard treatment sulfadoxine-pyrimethamine (SP). The study aims to understand how these treatments affect low birth weight and maternal health, considering factors like infections and inflammation. By conducting randomized controlled trials, the research seeks to identify the best approach to reduce the impact of malaria on pregnancy.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant women living in areas where malaria is common.
Not a fit: Patients who are not pregnant or those living in non-endemic malaria regions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved birth weights and healthier pregnancies for women in malaria-endemic regions.
How similar studies have performed: Previous studies have shown promising results with similar malaria prevention strategies, but this specific approach is still being evaluated for its effectiveness.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Roh, Michelle — University of California, San Francisco
- Study coordinator: Roh, Michelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.